Cardiology Unit, Department of Medical and Surgical Science, University of Foggia, Foggia, Italy.
Cardiovascular Diseases Unit, Department of Internal Medicine, S. Maria alle Scotte Hospital, University of Siena, Siena, Italy.
Eur J Clin Invest. 2021 Nov;51(11):e13624. doi: 10.1111/eci.13624. Epub 2021 Jun 15.
Over the last years, several trials offered new evidence on heart failure (HF) treatment.
For HF with reduced left ventricular ejection fraction, type 2 sodium-glucose cotransporter inhibitors, aside from sacubitril-valsartan, demonstrated extraordinary efficacy in ameliorating patients' prognosis. Some new molecules (eg vericiguat, omecamtiv mecarbil and ferric carboxymaltose) correct iron deficiency and have shown to be capable of furthering reducing the burden of HF hospitalisation. Finally, there is new evidence on the possible therapeutic approaches of HF patients with mid-range or preserved left ventricular ejection fraction.
This review aimed to revise the main novelties in the field of HF therapy and focus on how the daily clinical approach to patient treatment is changing.
在过去的几年中，多项试验提供了心力衰竭（HF）治疗的新证据。
对于射血分数降低的心力衰竭，除沙库巴曲缬沙坦外，2 型钠-葡萄糖共转运蛋白抑制剂在改善患者预后方面显示出非凡的疗效。一些新分子（如维立西呱、奥马曲拉和羧甲麦芽糖铁）可纠正缺铁，并且能够进一步降低心力衰竭住院的负担。最后，对于左心室射血分数中间值或保留的心力衰竭患者，有新的证据表明可能的治疗方法。
本综述旨在回顾心力衰竭治疗领域的主要新进展，并重点关注患者治疗的临床方法如何发生变化。
